Sonodynamic Therapy clinical trials at University of California Health
2 research studies open to eligible people
Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients With DIPG
open to eligible people ages 5 years and up
The primary objectives of this trial are to evaluate the safety and tolerability of sonodynamic therapy (SDT) using SONALA-001 and Exablate Type 2.0 device and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of MR-Guided Focused Ultrasound (MRgFUS) energy in combination with SONALA-001 in subjects with diffuse intrinsic pontine glioma Funding Source - FDA OOPD
at UCSF
Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2 in Subjects With Progressive or Recurrent GBM
open to eligible people ages 18 years and up
The primary objectives of this trial are to evaluate the safety, dose-limiting toxicities, maximum tolerated dose (MTD), maximum administered dose (MAD) and recommended Phase 2 dose (RP2D) for future study after a single treatment of SONALA-001 in combination with MRgFUS and to evaluate preliminary efficacy of sonodynamic therapy (SDT) using SONALA-001 and Exablate Type 2.0 device in subjects with progressive or recurrent GBM.
at UCSF
Our lead scientists for Sonodynamic Therapy research studies include Nicholas A Butowski, M.D. Sabine Mueller, MD.
Last updated: